{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T18:12:12Z","timestamp":1788804732977,"version":"build-2803163510"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Dar\u00e9 Bioscience"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>There are currently no Food and Drug Administration\u2013approved treatments for female sexual arousal disorder (FSAD), which is physiologically analogous to male erectile dysfunction.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>The study sought to test the systemic and local genital safety of topical sildenafil cream, 3.6% (sildenafil cream) among healthy premenopausal women with FSAD and their sexual partners over a 12-week treatment period.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a phase 2b, exploratory, randomized, placebo-controlled, double-blind study of sildenafil cream among healthy premenopausal women with FSAD. Safety was assessed by the frequency and incidence of treatment-emergent adverse events (TEAEs) among participants and their sexual partners. Participants recorded the incidence of TEAEs in a daily eDiary (electronic diary). Sexual partners were contacted within 72\u00a0hours of each sexual event in which investigational product was used. All participants used placebo cream for 1 month, during a single-blind run-in period, and then if eligible, were randomized 1:1 to sildenafil cream or placebo cream. Participants used their assigned investigational product over a 12-week double-blind dosing period. They attended monthly follow-up visits, in which their eDiary TEAE data were reviewed by the study staff and graded for severity and relationship to study product.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Outcomes<\/jats:title>\n                  <jats:p>The frequency and incidence of TEAEs among participants and their sexual partners.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>During the 12-week double-blind dosing period, there were 78 TEAEs reported by 29 of 99 sildenafil-assigned participants and 65 TEAEs reported by 28 of 94 placebo-assigned participants (P\u00a0=\u2009.76). All TEAEs were mild or moderate in severity. The most common treatment-related TEAE among active and placebo-assigned participants was application site discomfort. There were no differences in the number of treatment-related TEAEs among sildenafil cream vs placebo cream users (P\u00a0&amp;gt;\u2009.99). Four sildenafil cream participants and 3 placebo cream participants discontinued the study due to TEAEs involving application site discomfort (P\u00a0&amp;gt;\u2009.99). There were 9 TEAEs reported by 7 of 91 sexual partners exposed to sildenafil cream vs 4 TEAEs reported by 4 of 84 sexual partners exposed to placebo cream (P\u00a0=\u2009.54).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Implications<\/jats:title>\n                  <jats:p>These data support further clinical development of topical sildenafil cream for the treatment of FSAD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Strengths and Limitations<\/jats:title>\n                  <jats:p>Safety was assessed among participants and their sexual partners after 1357 and 1160 sexual experiences in which sildenafil cream or placebo cream were used, respectively. The phase 2b study was powered for the primary objectives of efficacy, rather than safety.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>These data demonstrate that topically applied sildenafil cream was safe and well tolerated by exposed users and their sexual partners.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jsxmed\/qdae089","type":"journal-article","created":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T12:35:44Z","timestamp":1720701344000},"page":"793-799","source":"Crossref","is-referenced-by-count":7,"title":["Safety of topical sildenafil cream, 3.6% in a randomized, placebo-controlled trial for the treatment of female sexual arousal disorder"],"prefix":"10.1093","volume":"21","author":[{"given":"Andrea R","family":"Thurman","sequence":"first","affiliation":[{"name":"Dar\u00e9 Bioscience , San Diego, CA 92122, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Johnson","sequence":"additional","affiliation":[{"name":"Dar\u00e9 Bioscience , San Diego, CA 92122, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A","family":"Cornell","sequence":"additional","affiliation":[{"name":"Strategic Science & Technologies, LLC , Cambridge, MA 02141, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Hatheway","sequence":"additional","affiliation":[{"name":"Dar\u00e9 Bioscience , San Diego, CA 92122, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel N","family":"Kim","sequence":"additional","affiliation":[{"name":"Institute for Sexual Medicine , San Diego, CA 92120, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon J","family":"Parish","sequence":"additional","affiliation":[{"name":"Weill Cornell Medical College , NY 10065, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clint","family":"Dart","sequence":"additional","affiliation":[{"name":"Premier Research , Morrisville, NC 27560, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R","family":"Friend","sequence":"additional","affiliation":[{"name":"Dar\u00e9 Bioscience , San Diego, CA 92122, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Goldstein","sequence":"additional","affiliation":[{"name":"Dar\u00e9 Bioscience , San Diego, CA 92122, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,31]]},"reference":[{"issue":"1","key":"2024090406282900100_ref1","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.sxmr.2020.05.001","article-title":"The evolution of the female sexual disorder\/dysfunction definitions, nomenclature, and classifications: a review of DSM, ICSM, ISSWSH, and ICD","volume":"9","author":"Parish","year":"2021","journal-title":"Sex Med Rev"},{"issue":"2","key":"2024090406282900100_ref2","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s10508-009-9535-1","article-title":"The DSM diagnostic criteria for female sexual arousal disorder","volume":"39","author":"Graham","year":"2010","journal-title":"Arch Sex Behav"},{"issue":"1","key":"2024090406282900100_ref3","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2307\/2136095","article-title":"A political history of the national sex survey of adults","volume":"26","author":"Laumann","year":"1994","journal-title":"Fam Plan Perspect"},{"issue":"2","key":"2024090406282900100_ref4","first-page":"133","article-title":"Female sexual interest\/arousal disorder: history of diagnostic considerations and their implications for clinical practice","volume":"37","author":"Witherow-Parkanyi","year":"2022","journal-title":"Psychiatr Hung"},{"issue":"4","key":"2024090406282900100_ref5","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/GRF.0b013e3181bf4982","article-title":"Diagnosis and treatment of female sexual arousal disorder","volume":"52","author":"Jayne","year":"2009","journal-title":"Clin Obstet Gynecol"},{"issue":"8","key":"2024090406282900100_ref6","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1080\/0092623X.2019.1623356","article-title":"Sexual motivation in couples coping with female sexual interest\/arousal disorder: a comparison with control couples","volume":"45","author":"Bockaj","year":"2019","journal-title":"J Sex Marital Ther"},{"issue":"1","key":"2024090406282900100_ref7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.sxmr.2021.07.003","article-title":"A systematic literature review of health-related quality of life measures for women with hypoactive sexual desire disorder and female sexual interest\/arousal disorder","volume":"10","author":"Lim-Watson","year":"2022","journal-title":"Sex Med Rev"},{"issue":"4","key":"2024090406282900100_ref8","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7257\/1053-816X.2010.30.4.247","article-title":"Treatment options for female sexual arousal disorder: part II","volume":"30","author":"Feldhaus-Dahir","year":"2010","journal-title":"Urol Nurs"},{"issue":"5","key":"2024090406282900100_ref9","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1023\/A:1019831906508","article-title":"Biochemical and physiological mechanisms of female genital sexual arousal","volume":"31","author":"Traish","year":"2002","journal-title":"Arch Sex Behav"},{"issue":"2","key":"2024090406282900100_ref10","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S0090-4295(02)01686-2","article-title":"Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction","volume":"60","author":"Corbin","year":"2002","journal-title":"Urology"},{"issue":"1","key":"2024090406282900100_ref11","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0090-4295(02)01663-1","article-title":"Type 5 phosphodiesterase expression in the human vagina","volume":"60","author":"D'Amati","year":"2002","journal-title":"Urology"},{"issue":"5","key":"2024090406282900100_ref12","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/ijir.2011.29","article-title":"Expression and distribution of key enzymes of the cyclic GMP signaling in the human clitoris: relation to phosphodiesterase type 5 (PDE5)","volume":"23","author":"Uckert","year":"2011","journal-title":"Int J Impot Res"},{"issue":"6","key":"2024090406282900100_ref13","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s00345-005-0014-6","article-title":"In vitro functional responses of isolated human vaginal tissue to selective phosphodiesterase inhibitors","volume":"23","author":"Uckert","year":"2005","journal-title":"World J Urol"},{"issue":"6","key":"2024090406282900100_ref14","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1111\/j.1743-6109.2007.00595.x","article-title":"Expression of messenger ribonucleic acid encoding for phosphodiesterase isoenzymes in human female genital tissues","volume":"4","author":"Uckert","year":"2007","journal-title":"J Sex Med"},{"issue":"5","key":"2024090406282900100_ref15","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.urology.2005.11.055","article-title":"Expression of cAMP and cGMP-phosphodiesterase isoenzymes 3, 4, and 5 in the human clitoris: immunohistochemical and molecular biology study","volume":"67","author":"Oelke","year":"2006","journal-title":"Urology"},{"issue":"Suppl 4","key":"2024090406282900100_ref16","doi-asserted-by":"crossref","first-page":"S152","DOI":"10.1038\/sj.ijir.3900596","article-title":"Female sexual arousal disorder: new insights","volume":"12","author":"Goldstein","year":"2000","journal-title":"Int J Impot Res"},{"issue":"6","key":"2024090406282900100_ref17","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1097\/01.ju.0000090966.74607.34","article-title":"Safety and efficacy of sildenafil citrate for the treatment of female sexual arousal disorder: a double-blind, placebo controlled study","volume":"170","author":"Berman","year":"2003","journal-title":"J Urol"},{"issue":"5","key":"2024090406282900100_ref18","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/j.fertnstert.2005.10.043","article-title":"Sildenafil improves sexual functioning in premenopausal women with type 1 diabetes who are affected by sexual arousal disorder: a double-blind, crossover, placebo-controlled pilot study","volume":"85","author":"Caruso","year":"2006","journal-title":"Fertil Steril"},{"issue":"4","key":"2024090406282900100_ref19","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/jama.300.4.395","article-title":"Sildenafil treatment of women with antidepressant-associated sexual dysfunction: a randomized controlled trial","volume":"300","author":"Nurnberg","year":"2008","journal-title":"JAMA"},{"issue":"5","key":"2024090406282900100_ref20","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1345\/aph.1G471","article-title":"Use of sildenafil for female sexual dysfunction","volume":"40","author":"Shields","year":"2006","journal-title":"Ann Pharmacother"},{"issue":"4","key":"2024090406282900100_ref21","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/nrurol.2009.25","article-title":"Sildenafil citrate for female sexual arousal disorder: a future possibility?","volume":"6","author":"Schoen","year":"2009","journal-title":"Nat Rev Urol"},{"issue":"7-8","key":"2024090406282900100_ref22","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1345\/aph.1L691","article-title":"Assessing the clinical efficacy of sildenafil for the treatment of female sexual dysfunction","volume":"43","author":"Brown","year":"2009","journal-title":"Ann Pharmacother"},{"issue":"2_Part_2","key":"2024090406282900100_ref23","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/j.1743-6109.2009.01599.x","article-title":"Phosphodiesterase type 5 inhibitors and female sexual response: faulty protocols or paradigms?","volume":"7","author":"Chivers","year":"2010","journal-title":"J Sex Med"},{"issue":"2","key":"2024090406282900100_ref24","article-title":"Preliminary efficacy of topical sildenafil cream for the treatment of female sexual arousal disorder: a randomized controlled trial","volume":"144","author":"Johnson","year":"2024","journal-title":"Obstet Gynecol"},{"issue":"1","key":"2024090406282900100_ref25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.fertnstert.2004.01.025","article-title":"Why consider vaginal drug administration?","volume":"82","author":"Alexander","year":"2004","journal-title":"Fertil Steril"},{"issue":"1","key":"2024090406282900100_ref26","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1749-6632.1997.tb48549.x","article-title":"Vaginal drug delivery: the first uterine pass effect","volume":"828","author":"Bulletti","year":"1997","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"2024090406282900100_ref27","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/13697137.2016.1196047","article-title":"Revised global consensus statement on menopausal hormone therapy","volume":"19","author":"de Villiers","year":"2016","journal-title":"Climacteric"},{"key":"2024090406282900100_ref28","article-title":"Phase 1 studies of topical cream in normal healthy men (SST-6006-001-01) and normal healthy postmenopausal women (SST-6006-008-01)","author":"Strategic Sciences and Technologies (SST)","year":"2014","journal-title":"Data on File with SST LLC"},{"key":"2024090406282900100_ref29","volume-title":"Prescribing Information VIAGRA (Sildenafil Citrate) Tablets, for Oral Use","author":"Food and Drug Administration"},{"key":"2024090406282900100_ref30","volume-title":"VIAGRA (Sildenafil Citrate) Prescribing Information","author":"Food and Drug Administration"},{"key":"2024090406282900100_ref31","volume-title":"Prescribing Information for Revatio","author":"Food and Drug Administration"},{"key":"2024090406282900100_ref32","volume-title":"Adcirca Prescribing Information","author":"Food and Drug Administration"},{"key":"2024090406282900100_ref33","first-page":"151","article-title":"Phosphodiesterase-5 inhibitors in management of pulmonary hypertension: safety, tolerability, and efficacy","volume":"2","author":"Buckley","year":"2010","journal-title":"Drug Healthc Patient Saf"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jsm\/advance-article-pdf\/doi\/10.1093\/jsxmed\/qdae089\/59002085\/qdae089.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/advance-article-pdf\/doi\/10.1093\/jsxmed\/qdae089\/59002085\/qdae089.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T19:46:47Z","timestamp":1725479207000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/21\/9\/793\/7724223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,31]]},"references-count":33,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,7,31]]},"published-print":{"date-parts":[[2024,9,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jsxmed\/qdae089","relation":{},"ISSN":["1743-6095","1743-6109"],"issn-type":[{"value":"1743-6095","type":"print"},{"value":"1743-6109","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,7,31]]}}}